This trial studies nivolumab and ipilimumab as possible treatments for uterine cancer. Nivolumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Ipilimumab is also a monoclonal antibody. The combination of nivolumab and ipilimumab may work better than nivolumab alone in treating patients with uterine cancer.
2 Primary · 5 Secondary · Reporting Duration: Time from start of treatment to time of progression or death, whichever occurs first, assessed at 6 months
Experimental Treatment
20 Total Participants · 2 Treatment Groups
Primary Treatment: Nivolumab · No Placebo Group · Phase 2
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: